MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway.

about

MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway.

Item

http://www.wikidata.org/entity/Q49740746

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

MiR-361-5p suppresses chemores ...... via the PI3K/Akt/mTOR pathway.

@en

MiR-361-5p suppresses chemores ...... via the PI3K/Akt/mTOR pathway.

@nl

type

Item

label

MiR-361-5p suppresses chemores ...... via the PI3K/Akt/mTOR pathway.

@en

MiR-361-5p suppresses chemores ...... via the PI3K/Akt/mTOR pathway.

@nl

prefLabel

MiR-361-5p suppresses chemores ...... via the PI3K/Akt/mTOR pathway.

@en

MiR-361-5p suppresses chemores ...... via the PI3K/Akt/mTOR pathway.

@nl

P1476

MiR-361-5p suppresses chemores ...... via the PI3K/Akt/mTOR pathway.

@en

P2093

JinPeng Zhu

http://www.w3.org/2001/XMLSchema#string

Lei Tian

http://www.w3.org/2001/XMLSchema#string

Ling Xie

http://www.w3.org/2001/XMLSchema#string

Zhifeng Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

FOXM1, a typical proliferation-associated transcription factor

The role of the Atg1/ULK1 complex in autophagy regulation

Molecular mechanisms of long noncoding RNAs

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKKβ/AMPKα/mTOR pathway

FoxM1 mediates resistance to herceptin and paclitaxel.

FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

P304

4886-4896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23513

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29435149

http://www.w3.org/2001/XMLSchema#string

P932

5797020

http://www.w3.org/2001/XMLSchema#string